

1 Research Progress of circRNA in Epithelial Mesenchymal 2 Transformation of Gastric Cancer

3
4 Zhuoya li^{1,2}, Xiaoyun Ding², Haojun Song²

5 ¹The Medical School of Ningbo University, Ningbo , Zhejiang , China

6 ²The Gastroenterology Department of Ningbo First Hospital , Ningbo , Zhejiang ,
7 China

8 Correspondence: dyyding@126.com; Tel: +86-13967854476

9 10 **Abstract**

11 With the continuous progress in modern medicine, the early detection rate of
12 gastric cancer has increased, and the mortality rate has decreased. However,
13 gastric cancer remains the third leading cause of cancer-related death worldwide,
14 with a high recurrence rate. Metastasis is the leading cause of death and
15 recurrence of gastric cancer, which greatly hinders treatment success. Cancer
16 development is a complex process involving multiple sequential steps. In the
17 metastatic cascade, local invasion may be considered an initial, crucial step in the
18 development of a malignant tumor, which leads to distant metastasis. Epithelial-
19 mesenchymal transformation (EMT) is one of the most important developmental
20 processes that occur during tumor invasion. EMT confers certain basic abilities to
21 cancer cells, such as migration, invasion and anti-apoptotic ability, thus initiating
22 and increasing metastasis. However, little is known about the molecular
23 mechanisms that promote EMT and gastric cancer cell metastasis. A number of
24 recent studies have found that circular RNAs (circRNAs) are associated with gastric

25 cancer EMT, regulating the EMT process and promoting the occurrence and
26 development of tumors. Because of their unique continuous circular structure,
27 circRNAs have relatively high stability in plasma and cells, making them more
28 suitable as diagnostic biomarkers in malignant tumors. Therefore, understanding
29 the mechanism of circRNAs in EMT in gastric cancer is an important research
30 direction to actively prevent tumor metastasis and improve the therapeutic effect
31 on advanced malignant tumors.

32 **Key words:** circRNAs, gastric cancer, EMT

33

34 **1.Introduction**

35 Gastric cancer is one of the most common gastrointestinal malignancies in the
36 world and the third leading cause of cancer death. In some western Asian countries,
37 particularly in eastern Asia (including Japan, South Korea and China), the incidence
38 has increased significantly[1]. The incidence of gastric cancer ranks third among
39 all cancers in China, and the death rate ranks second among cancer-related
40 deaths[2]. The 5-year survival rate for gastric cancer patients who are diagnosed
41 early exceeds 90%[3]. However, due to the atypical clinical symptoms of patients
42 with gastric cancer, early diagnosis is difficult, and the first diagnosis of most
43 patients is in the late stage[4]. Moreover, in advanced cases, the treatment cost is
44 high, and the benefit is small. The long-term prognosis of patients is not optimistic,
45 and the 5-year overall survival rate is less than 30%[5]. The main cause of death
46 and recurrence of gastric cancer is metastasis, which is the main obstacle in the
47 clinical treatment of gastric cancer, accounting for the majority of the causes of

48 gastric cancer death. Insufficient understanding of the molecular mechanism of the
49 development and progression of gastric cancer is also a major problem in the
50 diagnosis and treatment of gastric cancer. At present, the primary goal of gastric
51 cancer research is to improve survival rates through early diagnosis and effective
52 targeted therapy at various stages. Therefore, it is of great significance to study the
53 molecular mechanisms of invasion and metastasis of gastric cancer, which also
54 helps to identify new biomarkers for the diagnosis of gastric cancer patients.

55 Recent studies have found that epithelial-mesenchymal transition (EMT) is one
56 of the key steps in the invasion and metastasis of gastric cancer. Among the
57 numerous molecules and biochemical mechanisms involved in the EMT process,
58 circular RNAs (circRNAs) are one of the important molecules. Recent studies have
59 also shown that circRNAs are differentially expressed in a variety of human tumors
60 and play an indispensable role in the pathogenesis of cancer[6-8]; that is, they play
61 an important role in the occurrence and metastasis of cancer including gastric
62 cancer[9, 10]. Therefore, this paper will review the progress on circRNA-related
63 mechanisms in gastric cancer EMT.

64 **1.Basic overview of EMT**

65 In 1982, Greenberg and Hay first discovered the phenomenon of EMT in
66 lens cells[11]. They found that lens epithelial cells could form pseudopodium in
67 collagen gel and transform into mesenchymal cell-like morphology. Therefore,
68 they defined EMT as the biological process of epithelial cells transforming from
69 an epithelial phenotype to a dynamic mesenchymal phenotype under the action

70 of specific pathological or physiological factors. EMT can be divided into three
71 subtypes: type I EMT is related to embryonic development and also plays an
72 important role in postnatal growth and development; type II EMT is stimulated
73 by injury, and inflammatory repair is performed on damaged tissue, in which an
74 aberrant repair process can cause damage to normal epithelial cells and organs;
75 and type III EMT cells acquire interstitial invasion characteristics, which are
76 related to metastasis and dissemination[12]. With further research, EMT has
77 been gradually found to be closely related to pathophysiological processes such
78 as embryo development, wound repair, tissue fibrosis, tumor invasion and
79 metastasis, and tumor chemotherapy resistance[13, 14]. EMT is driven by the
80 inhibition of epithelial-related genes (such as E-cadherin) and the activation of
81 mesenchymal-related genes (such as fibroblast-specific protein 1 and
82 vimentin)[12, 14, 15]. At present, the specific regulatory mechanism of EMT is
83 still unclear. According to existing studies, signaling pathways such as TGF- β ,
84 Wnt/ β -catenin, Notch, Hedgehog, IL-6/STAT3, and NF- κ B can induce EMT
85 processes. Important transcription factors involved in EMT are Snail1, Snail2,
86 Twist1, Twist2, ZEB1, ZEB2, etc[16, 17]. In addition, recent studies have found
87 that many noncoding RNAs (ncRNAs) are also involved in the regulation of tumor
88 EMT, such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs)[18],
89 and circRNAs have also been found to be important regulators of EMT[19, 20].


90 **2. Basic overview of circRNA**

91 CircRNAs were first discovered by Sanger et al. in plant viroids in 1976, and

92 circRNAs were subsequently found in viruses and eukaryotes[21]. However, due
93 to their low expression levels, circRNAs were considered a byproduct of false
94 splicing and were not widely studied. As RNA research techniques develop, an
95 increasing number of circRNAs have been found, whereby reverse repeat
96 sequences, exon jumps, and RNA splicing have been shown to affect their
97 formation[22], and circRNAs have been increasingly found to occur and develop
98 in a variety of diseases[23, 24]. In particular, circRNAs play an important
99 regulatory role in tumor development[25, 26], however their characterization in
100 stomach cancer has just begun.

101 CircRNAs are endogenous ncRNAs that form a covalently closed
102 continuous circular structure without 5' to 3' polarity or polyadenylated tail[27].
103 This structure makes circRNAs more stable in cells and not easily degradable
104 by exonuclease. It is precisely because of their high conservation and stability
105 that the diagnosis of malignant tumors by circRNAs will take precedence over
106 other types of noncoding RNAs, which have great clinical potential to diagnose
107 diseases. CircRNAs are produced by an exon, an intron, or intergenic splicing,
108 and depending on their composition, are known as exon circRNAs, intron
109 circRNAs, or exon-intron circRNAs. The biological functions of the currently
110 known circRNAs include the following (Figure 1) [22, 28-31]: (1) regulation of
111 gene transcription; (2) regulation of selective shearing; (3) regulation of the
112 translation of parental genes; (4) regulation of the cell cycle; (5) sponge for
113 some proteins; (6) miRNA sponge, blocking the inhibition of miRNAs on target

114 genes; and (7) induction of the translation of n6-methyl adenosine (m6A).



115

116 Figure 1: The biological functions of the currently known circRNAs

117 3. Study on the function of EMT in gastric cancer

118 With the help of bioinformatics analysis, circRNA chip analysis and high-
 119 throughput sequencing technology, numerous circRNAs have been found to be
 120 involved in the development of gastric cancer[20, 25]. CircRNA microarray
 121 analysis was performed in 6 patients with gastric cancer by Gu et al. to
 122 investigate the differences in circRNA expression between tumor and adjacent
 123 nontumor tissues[32]. They found that 440 circRNAs were expressed differently
 124 in tumor samples, including 176 upregulated circRNAs and 264 downregulated
 125 circRNAs. In another study[33], hsa_circ_0014717 was identified as the target
 126 circRNA. The global circRNA expression profile in human gastric cancer was

127 measured by circRNA microarray, and the expression levels in gastric tissues
128 and gastric juice were studied. A total of 308 circRNAs were found to be
129 abnormally expressed in gastric cancer tissues, among which 107 were
130 upregulated (34.74%) and 201 were downregulated (65.26%). Among the RNAs
131 with differential expression, some circRNAs have been found to be related to
132 the proliferation, invasion and metastasis of gastric cancer cells[34, 35].
133 Studies on the role of circRNAs in gastric cancer may provide new ideas for the
134 diagnosis and treatment of gastric cancer. The recent discovery of circRNAs
135 related to EMT in gastric cancer provides a new direction for the diagnosis and
136 treatment of advanced gastric cancer.

137 As mentioned above, circRNAs have 7 different functions, among which,
138 the regulation of gene expression as a miRNA sponge has been studied in most
139 detail. Currently, there are 6 circRNAs found to be associated with EMT in gastric
140 cancer, among which 3 have been found to play a role as miRNA sponges. Some
141 are downregulated and act as tumor suppressors, while others are upregulated
142 and act as oncogenes during carcinogenesis. Table 1 summarizes all of these
143 circRNAs. CircCACTIN is upregulated in stomach cancer tissues and cell
144 lines[10]. It affects the proliferation, migration, invasion and EMT of stomach
145 cancer cells through a competing endogenous RNA (ceRNA) mechanism in the
146 circCACTIN/miR-331-3p/TGFBR1 axis. In this study, the authors also found that
147 circCACTIN and TGFBR1 had a consistent effect on cell phenotypes. As a result,
148 circCACTIN is expected to become a new target for cancer treatment. Liang M
149 et al[9]. showed a negative correlation between miR-195 and hsa_circ_006100
150 through bioinformatics analysis. Patients with high hsa_circ_006100 or low

151 miR-195 levels had high TNM stages, poor cell differentiation, and lymph node
152 metastasis. MiRNA-195 is targeted by hsa_circ_006100. Overexpression of
153 hsa_circ_006100 enhances cell activity and proliferation and promotes the
154 migration and invasion of MGC-803 and AGS cells. GPRC5A is predicted to be
155 the target of miRNA-195 and is upregulated in stomach cancer. In vivo studies
156 have shown that knockdown of hsa_circ_006100 delayed tumor growth,
157 reduced PCNA expression and upregulated miR-195 and BCL-2 expression,
158 which was restored by miR-195 inhibition via GPRC5A/EGFR signaling, and
159 changed the EMT phenotype in vivo. It has been verified that circRNA-006100
160 is correlated with gastric cancer proliferation, invasion, EMT, etc. and may
161 regulate the role of circRNAs in gastric cancer EMT through the miR-
162 195/GPRC5A signaling pathway. Li et al. found that the ectopic expression of
163 hsa_circ_104916 could effectively inhibit the proliferation, migration and
164 invasion of gastric cancer cells in vitro, and during the EMT process[35],
165 hsa_circ_104916 was shown to mediate an increase in the expression of
166 epithelial molecules (E-cadherin) and a decrease in mesenchymal molecules
167 (N-cadherin and vimentin) and a zinc finger transcription suppressor (SLUG).
168 However, the exact mechanism by which hsa_circ_104916 regulates the
169 expression of EMT-related molecules remains unclear. Similarly, the roles of
170 circ_0009910 and circRNA_0023642 in the signaling pathway of gastric cancer
171 EMT have not yet been identified. Precisely because the specific mechanism of
172 circRNA involvement in the tumor EMT process has not been clearly studied,
173 this may become a research direction of studies on tumor EMT in the next few
174 years.

175 Table 1: Expression and effect of circRNAs in gastric cancer tissues and cells

176

circRNA	References	Expression	Possible pathways	function
Circ_0009910	LIU M, LIU K-D, ZHANG L, et al.[36]	Up-regulated	needs further research	Proliferation, migration, invasion, and EMT
hsa_circ_0092303 (CIRCCACTIN)	Zhang L, Song X, Chen X, et al.[10]	Up-regulated	circCACTIN/miR-331-3p/TGFBR1 axis	Proliferation, migration, invasion, and EMT
hsa_circ_006100	M L, G H, Z L, et al.[9]	Up-regulated	miR-195/GPRC5A signal pathway	Proliferation, migration, invasion, apoptosis and EMT
circRNA_0023642	ZHOU L-H, YANG Y-C, ZHANG R-Y,	Up-regulated	demands for further research	Proliferation, migration,

	WANG P et al. [37]			invasion, apoptosis and EMT
ciRS-7 (CDR1as)	Hansen TB, Kjems J and Damgaard CK;[38]Zhao X, Dou W, He L, et al. [39]	Upregulate d or Downregulated	ciRS-7/miR-7axis, insulin-like growth factor-1 receptor (IGF1R)	Proliferation, migration, invasion, apoptosis and EMT
circ-104916	J L, L Z, Y Z, et al.[35]	Down-regulated	needs further research	Proliferation, migration, invasion, and EMT

177 Conclusion

178 Studies have confirmed that peripheral invasion and distant metastasis are
 179 important causes of death in patients with gastric cancer. Currently, molecular
 180 biomarkers used in clinical practice have low organ specificity and low correlation
 181 with the clinical stage of cancer. For example, CEA is common in gastrointestinal
 182 tumors, while CA19-9 is more common in various adenocarcinomas. If circRNAs are
 183 used as biomarkers for gastric cancer in the clinic, their tissue-specific expression

184 may help solve the problem of low organ specificity of existing markers and
185 contribute to clinical prognosis. An increasing number of studies have
186 demonstrated that EMT plays an important role in the migration and invasion of
187 gastric cancer and that circRNAs also play a key role in digestive tract tumors.
188 Therefore, understanding the regulatory effect of circRNAs on EMT and related
189 molecular mechanisms can provide new ideas for the control of gastric cancer
190 migration and invasion. However, compared with ncRNA, miRNA and lncRNA
191 research, research on circRNAs in gastric cancer is still in its infancy. Although many
192 functional circRNAs have been found and studied in gastric cancer, most studies
193 have focused on the relationship between their expression level and pathological
194 features. Studies on the relationship between circRNAs and EMT in gastric cancer
195 are few and far between. The role of circRNAs in gastric cancer EMT still needs to
196 be further confirmed by larger sample sizes, more data and cell experiments, and
197 whether circRNAs can be truly applied in tumor diagnosis and treatment is still
198 unknown. Further study on the regulatory mechanism of circRNAs in EMT will help
199 reveal the mechanism of circRNAs in tumor metastasis and help find new targeted
200 therapy strategies for EMT, which will have a profound impact on the improvement
201 of the diagnosis and treatment of gastric cancer. In addition, how to efficiently
202 transfer circRNAs or si-circRNAs to the exact lesion site without side effects is still
203 a problem to be solved in clinical application. With the progress of molecular biology
204 and bioinformatics technology, we hope to conduct more basic research on
205 circRNAs, reveal the pathophysiological functions of circRNAs, develop circRNA-

206 based treatment strategies, and integrate them into clinical practice safely and
207 successfully.

208

209 **Abbreviations:**

210 EMT: Epithelial-mesenchymal transformation:

211 circRNA: Circular RNA

212 lncRNA: long noncoding RNA

213 miRNA: microRNA

214 ncRNA: noncoding RNA

215 ceRNA: endogenous RNA

216

217 **Ethics declarations**

218 **Consent for publication**

219 Not applicable.

220 **Competing interests**

221 The authors declare that there is no conflict of interest regarding the publication of
222 this paper. This study hadn't received any help from foundation or commence tissue.

223 **Authors' contributions**

224 Zhuoya Li wrote the paper and collected the data. Haojun Song conceived and designed
225 the analysis. Xiaoyun Ding provided with valuable guidance in every stage of the
226 writing of this thesis.

227 **Acknowledgements**

228 Not applicable

229

230 References

- 231 1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A., Global cancer
232 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
233 in 185 countries. *CA Cancer J Clin* **2018**.
- 234 2. Chen, W.; Zheng, R.; Baade, P. D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X. Q.; He, J.,
235 Cancer statistics in China, 2015. *CA: A Cancer Journal for Clinicians* **2016**, 66, (2), 115-132.
- 236 3. Isobe, Y.; Nashimoto, A.; Akazawa, K.; Oda, I.; Hayashi, K.; Miyashiro, I.; Katai, H.; Tsujitani,
237 S.; Kodera, Y.; Seto, Y.; Kaminishi, M., Gastric cancer treatment in Japan: 2008 annual report
238 of the JGCA nationwide registry. *Gastric Cancer* **2011**, 14, (4), 301-16.
- 239 4. Yoon, H.; Kim, N. J. G.; Liver, Diagnosis and Management of High Risk Group for Gastric
240 Cancer. **2015**, 9, (1), 5.
- 241 5. HK, W.; H, C.; R, H.; D, S.; XS, W.; F, B.; JV, A.; CJ, J.; A, B.; R, M. -G.; C, S.; G, A. e. S.; WQ, C.;
242 OJ, O.; B, R.; MJ, S.; H, Y.; T, M.; M, B. -L.; H, S.; TC, T.; MP, C.; Lancet, J., Global surveillance
243 of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279
244 population-based registries in 67 countries (CONCORD-2).%A Allemani C. **2015**, 385,
245 (9972), 977-1010.
- 246 6. Li, P.; Chen, S.; Chen, H.; Mo, X.; Li, T.; Shao, Y.; Xiao, B.; Guo, J., Using circular RNA as a
247 novel type of biomarker in the screening of gastric cancer. *J Clinica Chimica Acta* **2015**,
248 444, 132-136.
- 249 7. Huang, G.; Zhu, H.; Shi, Y.; Wu, W.; Cai, H.; Chen, X., cir-ITCH Plays an Inhibitory Role in
250 Colorectal Cancer by Regulating the Wnt/ β -Catenin Pathway. *Plos One* **2015**, 10, (6),
251 e0131225.
- 252 8. Qin, M.; Liu, G.; Huo, X.; Tao, X.; Sun, X.; Ge, Z.; Yang, J.; Fan, J.; Liu, L.; Qin, W.,
253 Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular
254 carcinoma. *Cancer Biomarkers* **2016**, 16, (1), 161-169.
- 255 9. M, L.; G, H.; Z, L.; Q, W.; Z, Y.; Z, L.; H, L.; M, L.; X, Z.; Y, Z., Elevated levels of hsa_circ_006100
256 in gastric cancer promote cell growth and metastasis via miR-195/GPRC5A signalling. *Cell/
257 Prolif.* **2019**, e12661.
- 258 10. Zhang, L.; Song, X.; Chen, X.; Wang, Q.; Zheng, X.; Wu, C.; Jiang, J., Circular RNA
259 CircCACTIN Promotes Gastric Cancer Progression by Sponging MiR-331-3p and
260 Regulating TGFBR1 Expression. *Int J Biol Sci* **2019**, 15, (5), 1091-1103.
- 261 11. G, G., Epithelia suspended in collagen gels can lose polarity and express characteristics of
262 migrating mesenchymal cells. *The Journal of cell biology* **1982**, 1, (95).
- 263 12. Kalluri, R.; Weinberg, R. A., The basics of epithelial-mesenchymal transition. *Journal of
264 Clinical Investigation* **2015**, 119, (6), 1420-1428.
- 265 13. JP, T.; H, A.; RY, H.; Cell, N. M. J., Epithelial-mesenchymal transitions in development and
266 disease. *Cell* **2009**, 139, (5), 871-90.
- 267 14. Nieto, M. A. J. I. J. o. D. B., Epithelial-Mesenchymal Transitions in development and disease:
268 old views and new perspectives. *The International Journal of Developmental Biology* **2009**,

- 269 53, (8-10), 1541-1547.
- 270 15. Yadi; Binhua; Sinica, Z. J. A. B. E. B., New insights of epithelial-mesenchymal transition in
271 cancer metastasis. *Journal of biochemistry and biophysics: English edition* **2010**, 40, (7),
272 643-650.
- 273 16. Yang, J.; Weinberg, R. A., Epithelial-Mesenchymal Transition: At the Crossroads of
274 Development and Tumor Metastasis. *Developmental Cell* **2008**, 14, (6), 818-829.
- 275 17. Craene, B. D.; Berx, G., Regulatory networks defining EMT during cancer initiation and
276 progression. *Nature Reviews Cancer* **2013**, 13, (2), 97-110.
- 277 18. Ceppi, P.; Peter, M. E., MicroRNAs regulate both epithelial-to-mesenchymal transition and
278 cancer stem cells. *Oncogene* **2014**, 33, (3), 269.
- 279 19. Yochum, Z. A.; Burns, T. F., TWIST1 regulation of circRNA: a novel mechanism to promote
280 epithelial-mesenchymal transition in hepatocellular carcinoma. *Noncoding RNA Investig*
281 **2018**, 2.
- 282 20. Luo, B.; Tang, C. M.; Chen, J. S., circRNA and gastrointestinal cancer. *J Cell Biochem* **2019**.
- 283 21. Sanger, H. L.; Klotz, G.; Riesner, D.; Gross, H. J.; Kleinschmidt, A. K., Viroids are Single-
284 Stranded Covalently Closed Circular RNA Molecules Existing as Highly Base-Paired Rod-
285 Like Structures. *Proc Natl Acad Sci U S A* **1976**, 73, (11), 3852-3856.
- 286 22. Jeffrey, W., Circular RNA and Splicing: Skip Happens. *Journal of Molecular Biology* **2015**,
287 427, (15), 2411-2413.
- 288 23. Piwecka, M.; Glažar, P.; Hernandez-Miranda, L. R.; Memczak, S.; Wolf, S. A.; Rybak-Wolf,
289 A.; Filipchyk, A.; Klironomos, F.; Cerda Jara, C. A.; Fenske, P., Loss of a mammalian circular
290 RNA locus causes miRNA deregulation and affects brain function. *Science* **2017**, 357,
291 (6357), eaam8526.
- 292 24. Li, X.; Liu, C. X.; Xue, W.; Zhang, Y.; Jiang, S.; Yin, Q. F.; Wei, J.; Yao, R. W.; Yang, L.; Chen, L.
293 L., Coordinated circRNA Biogenesis and Function with NF90/NF110 in Viral Infection.
294 *Molecular Cell* **2017**, 67, (2), 214.
- 295 25. Jiang, F.; Hong, F.; Shah, M. W.; Shen, X., Circular RNAs as diagnostic biomarkers in gastric
296 cancer: A meta-analysis review. *Pathol Res Pract* **2019**, 215, (6), 152419.
- 297 26. Lei, B.; Tian, Z.; Fan, W.; Ni, B., Circular RNA: a novel biomarker and therapeutic target for
298 human cancers. *Int J Med Sci* **2019**, 16, (2), 292-301.
- 299 27. Chen, L. L.; Yang, L., Regulation of circRNA biogenesis. *Rna Biology* **2015**, 12, (4), 381-388.
- 300 28. Julia, S.; Charles, G.; Peter Lincoln, W.; Norman, L.; Brown, P. O., Circular RNAs are the
301 predominant transcript isoform from hundreds of human genes in diverse cell types. *Plos*
302 *One* **2012**, 7, (2), e30733.
- 303 29. Li, Z.; Huang, C.; Bao, C.; Chen, L.; Lin, M.; Wang, X.; Zhong, G.; Yu, B.; Hu, W.; Dai, L., Exon-
304 intron circular RNAs regulate transcription in the nucleus. *Nature Structural Molecular*
305 *Biology* **2015**, 22, (3), 256-264.
- 306 30. Qu, S.; Yang, X.; Li, X.; Wang, J.; Gao, Y.; Shang, R.; Sun, W.; Dou, K.; Li, H., Circular RNA: A
307 new star of noncoding RNAs. *Cancer Letters* **2015**, 365, (2), 141-148.
- 308 31. Zhang, Y.; Zhang, X.-O.; Chen, T.; Xiang, J.-F.; Yin, Q.-F.; Xing, Y.-H.; Zhu, S.; Yang, L.; Chen,
309 L.-L., Circular Intronic Long Noncoding RNAs. *Molecular Cell* **2013**, 51, (6), 792-806.
- 310 32. Gu, W.; Sun, Y.; Zheng, X.; Ma, J.; Hu, X. Y.; Gao, T.; Hu, M. J., Identification of Gastric
311 Cancer-Related Circular RNA through Microarray Analysis and Bioinformatics Analysis.
312 *BioMed Research International* **2018**, 2018, (12), 1-9.

- 313 33. Shao, Y.; Li, J.; Lu, R.; Li, T.; Yang, Y.; Xiao, B.; Guo, J., Global circular RNA expression profile
314 of human gastric cancer and its clinical significance. *Cancer Med* **2017**, 6, (6), 1173-1180.
- 315 34. Rong, D.; Dong, C.; Fu, K.; Wang, H.; Tang, W.; Cao, H., Upregulation of circ_0066444
316 promotes the proliferation, invasion, and migration of gastric cancer cells. *Onco Targets*
317 *Ther* **2018**, 11, 2753-2761.
- 318 35. J, L.; L, Z.; Y, Z.; L, Z.; H, L.; D, C.; H, C.; J, Y.; X, Q.; G, L., Circ-104916 is downregulated in
319 gastric cancer and suppresses migration and invasion of gastric cancer cells. *OncoTargets*
320 *therapy* **2017**, 10, (undefined), 3521-3529.
- 321 36. LIU, M.; LIU, K.-D.; ZHANG, L.; CAI, J.; YAO, H.-W.; BAI, Y.-K.; ZHANG, Z.-T., Circ_0009910
322 regulates growth and metastasis and is associated with poor prognosis in gastric cancer.
323 *European Review for Medical and Pharmacological Sciences* **2018**, 22, 8248-8256.
- 324 37. ZHOU, L.-H.; YANG, Y.-C.; ZHANG, R.-Y.; WANG, P.; PANG, M.-H.; LIANG, L.-Q.,
325 CircRNA_0023642 promotes migration and invasion of gastric cancer cells by regulating
326 EMT. *European Review for Medical and Pharmacological Sciences* **2018**, 22, 2297-2303.
- 327 38. Hansen, T. B.; Kjems, J.; Damgaard, C. K., Circular RNA and miR-7 in cancer. *Cancer Res*
328 **2013**, 73, (18), 5609-12.
- 329 39. Zhao, X.; Dou, W.; He, L.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.;
330 Fan, D., MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by
331 targeting insulin-like growth factor-1 receptor. *Oncogene* **2013**, 32, (11), 1363-72.

332